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Summary The biodistribution of no-carrier-added (n.c.a) meta-[131I]iodobenzylguanidine ([131I]MIBG) and
that prepared by the standard isotopic exchange method were compared in athymic mice bearing SK-N-SH
human neuroblastoma xenografts. No advantage in tumour uptake was observed for the n.c.a. preparation.
BALB/c nu/nu mice exhibited lower uptake in highly innervated normal tissues (heart and adrenals) than
normal BALB/c mice. In another experiment, the distribution of n.c.a. [131I]MIBG in the absence or presence
(3 -9 jg) of MIBG carrier was determined. At both 4 h and 24 h, the heart uptake was reduced by a factor of
1.5 even at a dose of 3 mg MIBG. Tumour uptake was not significantly altered by various amounts of
unlabelled MIBG at either time point.
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Radioiodinated meta-iodobenzylguanidine (MIBG), which is
an analogue of noradrenaline has found widespread
application in the management of neuroendocrine tumours
such as phaeochromocytoma and neuroblastoma (Feine et
al., 1987; McEwan et al., 1985; Sisson et al., 1984; Troncone
et al., 1987). With regard to its diagnostic use, [1231]MIBG
and ['1I]MIBG imaging has been found to be quite sensitive
and specific for lesion localisation. For example, in the case
of neuroblastoma, false-positive scans are virtually non-
existent and the number of false-negative scans is generally
low (Mastrangelo, 1987). Iodine-131-labelled MIBG is under
active investigation for the targeted radiotherapy of
neuroblastoma (Klingebiel et al., 1989; Garaventa et al.,
1991). The responses observed in some patients have been
highly encouraging; however, it is clear that improvements in
this treatment approach are needed.
One factor which could affect the efficacy of ['31I]MIBG is
the specific activity of the radiopharmaceutical. Radio-
iodinated MIBG, as currently used in the clinic, is prepared
by an isotopic exchange method (Ex-['31I]MIBG) (Mangner et
al., 1982). This method yields preparations with a maximum
specific activity of the order of 100 Ci mmol-1 and hence
includes significant levels of carrier MIBG. For example, a
typical therapy dose of ['1I]MIBG contains about 200 ,ug of
carrier MIBG per kg of body weight (Fielding et al., 1991).
As MIBG is taken up in neuroblastoma cells in vitro and
innervated tissues such as heart and adrenals in vivo primarily
by a saturable mechanism (Wieland et al., 1981; Smets et al.,
1989; Jaques et al., 1987), one would expect that increasing
the specific activity of radioiodinated MIBG could lead to an
increase in tracer accumulation in target tissues. However,
conflicting results on the effect of specific activity on MIBG
distribution have been reported. For example, high and
relatively constant myocardial uptake of [125I]MIBG was
reported over a wide range of specific activity; however, the
greatest heart accumulation was observed with the lowest
specific activity (Wieland et al., 1981); similar behaviour was
seen in the adrenals (Wieland et al., 1984). On the contrary,
saturation of heart uptake with low specific activity
[231I]MIBG also has been reported in a subsequent study
(Mock and Tuli, 1988).
A number of laboratories have investigated the effect of
specific-activity on the interaction of MIBG with tumour
cells. In vitro studies using SK-N-SH human neuroblastoma
cells have demonstrated that high specific activity ['3'I]MIBG
was more cytotoxic than a low specific activity preparation at
the same radioactivity dose level (Bruchelt et al., 1988).
However, in a preliminary report no significant difference in
tumour uptake was observed in vivo between ['31I]MIBG
preparations of high and low specific activities in mice
bearing SK-N-SH xenografts (Rutgers et al., 1991).
Recently, we have developed a no-carrier-added (n.c.a.)
synthesis of radioiodinated MIBG (Vaidyanathan and
Zalutsky, 1993, 1995). With the availability of this labelling
chemistry, investigations of the effect of specific activity on
MIBG accumulation can now be extended to the n.c.a. level.
We and others have shown that in vitro, the specific binding
of n.c.a. [I31/125I]MIBG to human neuroblastoma cell lines
remained constant over a 2-3-log activity range while that of
Ex-['311125I]MIBG dropped by a factor of 7 (Vaidyanathan
and Zalutsky, 1993; 1995; Mairs et al., 1995), suggesting a
lack of saturability for the n.c.a. preparation. The myocardial
and adrenal uptake of the n.c.a. preparation was also found
to be significantly higher than that observed for Ex-
[13'1]MIBG. Furthermore, about an order of magnitude
higher activity levels of Ex-[3'I]MIBG were necessary to
have the same cytotoxic effect as seen with n.c.a. ['31I]MIBG
(Vaidyanathan et al., 1994).
Recently, the tissue distribution of n.c.a. ['31I]MIBG and a
commercially available lot of this tracer prepared by the
exchange reaction have been compared in mice bearing SK-
N-BE(2C) human neuroblastoma xenografts (Mairs et al.,
1995). Highly encouraging results were obtained; the
accumulation of n.c.a. ['1I]MIBG was significantly higher
in tumour (as well as other target tissues such as heart and
adrenals) and more favourable tumour-to-non-target normal
tissue ratios were also seen for n.c.a. ['311]MIBG.
The current study was undertaken to determine whether
n.c.a. ['31I]MIBG would also offer a significant advantage in
tumour accumulation in another human neuroblastoma
xenograft model. The SK-N-SH xenograft model was
selected for these experiments because a previous investiga-
tion in this model failed to show an increase in tumour
localisation with increasing specific activity (Rutgers et al.,
1991). Our results suggest that the strain of the animal and
the nature of the tumour line must be considered in
interpreting specific activity effects on MIBG distribution.
Materials and methods
General
Radioiodine was obtained as a sodium ['311]iodide or sodium
['25I]iodide solution in 0.1 N sodium hydroxide (NaOH) from
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DuPont-New England Nuclear (North Billerica, MA, USA).
Meta-iodobenzylguanidine hemisulphate was purchased from
Sigma (St Louis, MO, USA). SK-N-SH human neuroblasto-
ma cells were obtained from American Type Culture
Collection (Rockville, MD, USA). The tissue culture
medium (JRH Biosciences, Lenexa, KS, USA) was made by
mixing 440 ml of RPMI-1640, 50 ml of Serum Plus, 5 ml of
penicillin-G/streptomycin (5000 U of penicillin and 5000 ,ug
of streptomycin per ml) and 5 ml of glutamine (200 mM in
saline). The cells were grown at 37°C in a humidified
incubator in a 5% carbon dioxide atmosphere.
Preparation of n.c.a [J311125I]MIBG
No-carrier-added ['31I]MIBG was prepared from 3-(tri-
methylsilylbenzylguanidine (TMSBG) as reported previously
(Vaidyanathan and Zalutsky, 1993). Briefly, to the required
amount of sodium [1311]iodide in 1-3 jl of 0.1N NaOH was
added 10 pl of a 0.3 M solution of N-chlorosuccinimide in
trifluoroacetic acid, followed by TMSBG in trifluoroacetic
acid (5 ,ul of 0.1 M solution). After 5 min at room
temperature, the product was isolated by reverse-phase high
pressure liquid chromatography (HPLC) in more than 90%
radiochemical yield. The HPLC fractions containing
['311]MIBG were pooled and most of the tetrahydrofuran
present in the HPLC eluent was removed with a stream of
argon and the remaining solution was passed through an
activated C18 solid-phase cartridge (Waters). After washing
with 2 x 5 ml of water, 1 ml of 5 mm acetate buffer (pH 4.5)
was passed through the cartridge. The activity was
subsequently eluted with four 250 ,ul portions of methanol.
The methanol portions containing the n.c.a. ['3'I]MIBG were
pooled, evaporated to dryness and reconstituted in phos-
phate-buffered saline (PBS). The same protocol was followed
for the preparation of n.c.a. ['25I]MIBG.
Ex-[131I]MIBG was prepared by the standard method
(Mangner et al., 1982) at the Duke University Radiopharmacy
and was supplied as a solution in 5 mM acetate buffer (pH 4.5).
The specific activity was 4-5 mCi (148- 185 MBq) per mg and
the activity concentration was about 5 mCi (185 MBq) ml-'.
The preparation was diluted in PBS before injection.
No-carrier-added ['31I]MIBG was prepared just before
each tissue distribution experiment and was isolated by
HPLC; the radiochemical purity was generally more than
99%. The purity of Ex-['31I]MIBG, determined by HPLC,
was more than 95%.
Experimental animals
Athymic mice were obtained from a closed breeding colony
maintained at the Duke University Cancer Center Isolation
Facility. Six-week-old BALB/c nu/nu mice weighing 18-22 g
were used in this study. In one experiment, normal male
BALB/c mice weighing 25-28 g were used. All animal
experimentation was carried out in accordance with a
protocol approved by the Duke University Institutional
Animal Care and Use Committee.
Xenograft model
After testing for mycoplasma, cells were grown as monolayers
in the tissue culture media described above. Cells (108 per ml)
in serum-free medium were initially injected subcutaneously in
theright flank of a few mice and tumours were allowed to grow for about 30 days. The tumours were isolated, homogenised and 100 jul of homogenate was injected into mice. Tissue
distribution studies were performed about 30 days later when
tumours had reached a volume of about 500 - 1000 mm3.
Biodistribution measurements
A total of four experiments were performed. In all
experiments, groups of five mice were used for each time
point. At selected intervals mice were killed with an overdose
of halothane, dissected and tissues of interest were removed.
After washing with saline, blot-drying and weighing, the
tissues were counted for 13"I activity in an automated gamma
counter along with injection standards. The percentage of the
injected dose per gram of tissue (%ID g-') was calculated for
all tissues of interest using an in-house computer program.
Although there were no significant differences between the
organ weights of normal and nude mice, these values (from
first three experiments; a paired-label protocol was used for
the last experiment) were normalised to a 25 g mouse to
minimise any influence the differential organ weights and
blood volume may have on the tissue uptake. Tumour sizes
in all groups within each experiment were not significantly
different. An independent Student's t-test was used to
determine statistical significance of differences observed
between experimental groups. A P<0.05 was considered to
be statistically significant.
In the first experiment, athymic mice bearing subcutaneous
SK-N-SH xenografts were injected intravenously with either
7 pCi (0.3 MBq; containing 2 pg of carrier MIBG) of Ex-
[l3I]MIBG or 11 ,pCi (0.4 MBq) of n.c.a. ['3'I]MIBG. Groups
of animals were killed at 4, 12, 24 and 48 h post-injection and
the tissue distribution of "3'I activity was determined. A
second experiment was performed to determine whether the
mouse strain influenced tracer distribution. Both athymic
mice (without xenografts) and normal BALB/c mice were
injected intravenously with 12 pCi of either Ex-['31I]MIBG
(0.4 MBq; 2.3 pg of MIBG) or n.c.a. ['3'I]MIBG and the
tissue distribution was determined at 1 and 4 h post-injection.
In the third experiment, 5 pCi (0.2 MBq) of n.c.a. [1311I]MIBG
was administered to athymic mice with SK-N-SH xenografts
with or without carrier MIBG (3, 6 or 9 ug per mouse) and
the tissue uptake was determined at 4 and 24 h post-injection.
Finally, to determine whether route of administration
influenced tissue distribution, a paired-injection protocol
was performed; five mice were injected with 6 pCi (0.2
MBq) of n.c.a. [1311]MIBG via the tail vein and 7 pCi (0.3
MBq) of n.c.a. [1251]MIBG was given by the intraperitoneal
route. The tissue distribution of both radionuclides was
determined at 24 h post-injection using a dual-channel
gamma-counter.
Results
The first biodistribution experiment was performed to
compare the target and non-target organ uptake of n.c.a.
['31I]MIBG with that of an exchange preparation containing 2
pg of MIBG carrier. As summarised in Table I, both
preparations were characterised by a rapid tissue clearance
of 131 activity. Selective targeting in highly innervated normal
tissues, i.e. heart and adrenals, was observed; however, the
%ID g-1 levels were less than anticipated based on previous
studies in normal mice. In general, no clear advantage was
seen for the n.c.a. preparation. Except the 12 h time point,
the heart uptake was similar for both preparations. The heart
uptake of n.c.a. ['311]MIBG at 12 h (2.5+0.3%ID g-1) was
slightly higher than that of exchange preparation
(2.1 +0.3%ID g-) and the difference was statistically
significant (P < 0.05). Adrenal uptake was also similar for
both preparations except at 24 h, when that of Ex-['31I]MIBG
was slightly higher (P < 0.05). Tumour weights determined at
necropsy for the animals receiving n.c.a. [I13]MIBG were not
significantly different than those receiving Ex-[131I]MIBG. For
example, in the 4 h post-injection groups, tumour weights
were 0.55+0.29 g and 0.51 +0.29 g, for the n.c.a. and Ex
groups, respectively. Accumulation in SK-N-SH xenografts
remained constant for the first 12 h and then declined
gradually thereafter. No statistically significant advantage in
tumour uptake was observed for the n.c.a. preparation.
Thyroid accumulation of n.c.a. ['3II]MIBG was consistently
2-3 times lower than that of the exchange preparation,
suggesting more favourable radiochemical purity, stability or
a greater inertness to deiodination in vivo.Specific activity effect on MBIG uptake
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Table I Biodistribution of [131I]MIBG (n.c.a. and exchange preparation) in nude mice with SK-N-SH human neuroblastoma xenografts
4 h
Ex N.c.a.
6.1 1.0
12.1 1.2
3.5 0.5
3.4 + 0.5
3.4 ±0.5
2.0 +0.2
0.5 +0.1
0.6 +0.0
3.7 0.5
7.5 +0.4
5.6 ±0.8
2.3 ±0.3
1.5 ±0.3
0.1 +0.1
3.2 ±0.3
6.5 1.3
10.0 2.4
3.3 ±0.4
2.6 ±0.5
2.5 ±0.6
1.6 ±0.4"
0.3 + 0.0"
0.3 0.1"
2.4i0.7"
4.7i0.6"
5.5+1.0
1.3 i0.3"
0.9 +0.
0.1 +0.1
2.7 1.0
Per cent injected dose per grama
12 h 24 h
Ex N.c.a. Ex
2.1+0.3
9.0 +2.4
1.4+0.2
1.5 ±0.2
1.1 +0.2
1.0 +0.4
0.7+0.4
0.2 +0.1
1.5 ±0.5
2.0 + 0.3
2.7+ 0.3
0.6+ 0.1
0.5 ±0.1
0.1 +0.1
2.6+0.3
2.5 +0.3b
7.3 ±2.3
1.3 ±0.2
1.5 ±0.2
1.1 +0.3
0.7 0.1
0.4±0.1"
0.2 +0.1
1.7 ± 0.5
2.4±0.5
3.2+ 1.1
0.5 ± 0.2
0.4+ 0.1
0.2 +0.1
2.9 ±0.6
1.0 ±0.2
7.8 3.4
0.6 +0.1
0.8 ±0.2
0.5 ±0.1
0.5 ±0.2
0.8 +0.1
0.1 +0.0
1.0 +0.1
1.2±0.3
1.6±0.3
0.3 ±0.0
0.3 0 0.1
0.0 +0.0
1.8 ±0.6
N.c.a.
0.7 ±0.2
4.6+1.3b
0.4 1.0b
0.7 ±0.2
0.4+0.1
0.2± 1.0b
0.4+0.1b
0.1 +0.0
0.6+0.1b
1.0+0.6
1.0±0.3b
0.3 +0.1
0.2 0.0
0.0 +0.0
1.8 ±0.2
48 h
Ex N.c.a.
0.3 0.1
4.4 1.2
0.2±0.0
0.2±0.1
0.1 +0.0
0.2+0.0
0.7 0.2
0.0 +0.0
0.5 +0.2
0.4 +0.2
0.3 ±0.1
0.1 +0.0
0.1 +0.0
0.0+0.0
1.5 +0.4
0.3 +0.1
5.9+ 3.1
0.1 +0.0
0.3 +0.1
0.2 0. 1b
0.1 + 0.0"
0.3 + 0. 1
0.0 +0.0
0.3 +0.1
0.3 + 0.1
0.3 0.1
0.1+0.0
0.1 +0.0
0.0 +0.0
1.2 +0.4
aMeanis.d. (n = 5); values normalised to a 25 g mouse. bDifference between Ex and n.c.a. statistically significant (P<0.05; determined by an
independent Student's t-test); c%ID/organ.
The second experiment was designed to investigate the
possibility that the nature of the mouse strain could influence
the tissue distribution pattern of ['31I]MIBG. As shown in
Figure 1, myocardial uptake of ["3'I]MIBG was greater in
normal BALB/c mice than in athymic BALB/c mice. For
example, with the n.c.a. preparation, heart uptake at 4 h was
14.3 +2.8% ID/g in normal mice compared with 7.0+1.1%
ID g-' for athymic animals (P<0.05). Heart uptake of the
Ex preparation was also reduced in athymic mice, and in
both species a myocardial delivery advantage was observed
for n.c.a. ['31I]MIBG. Similarly, the adrenal uptake of both
preparations in nude mice was significantly lower than in
normal mice; however, within each species, no significant
differences were seen when the uptake of two preparations in
this tissue was compared. Unlike the previous study, thyroid
uptake for n.c.a. ['3'I]MIBG (normal, 0.41 +0.09%; athymic,
0.48+0.12% at 1 h) was similar to that for Ex-['31I]MIBG
(normal, 0.63+0.09%, athymic, 0.43+0.09%).
To confirm that differences in radiopharmaceutical
(radiochemical purity, presence of unlabelled impurities)
did not obscure potential specific activity related effects, an
additional experiment was performed in which n.c.a.
['3'I]MIBG was administered alone, or with varying
quantities of authentic MIBG carrier, to athymic mice with
SK-N-SH xenografts. Carrier levels ranged from 3-9 jug per
animal to encompass doses used in clinical therapy. As
shown in Figure 2, tumour uptake at both time points
revealed small differences which were not statistically
significant suggesting that unlabelled MIBG in this dose
range has no effect on the tumour uptake. At both 4 and
24 h, the heart uptake was reduced by a factor of 1.5 by the
addition of 3 ,ug of MIBG. A less dramatic effect was
observed in adrenals; 6 jg of MIBG was necessary to cause
a significant reduction at 4 h. At 24 h, no clear trend in
adrenal uptake vs MIBG level was seen. With regard to
normal tissues lacking a specific uptake mechanism for
MIBG, no significant differences in uptake were seen among
the four dose groups at either time point.
An additional group of tumour-bearing mice was injected
with n.c.a. ['1'I]MIBG intravenously and ['251]MIBG by the
intraperitoneal route and killed 24 h later. Although the
tumour uptake when the activity was injected intravenously
was about 50% higher than that for intraperitoneal
administration (3.3+0.9% ID g-' vs 2.2+0.6% ID g-'),
the difference was not statistically significant. With the
exception of the stomach and intestines, which had higher
uptake of the intraperitoneally administered radiopharma-
ceutical, no significant differences in MIBG uptake related to
route of delivery were observed.
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Figure 1 Uptake of [131I]MIBG in the heart and adrenals of
non-tumour bearing BALB/c nu/nu mice and normal BALB/c
mice 4 and 24h after injection. E, athymic mice; =, normal
mice. (a) n.c.a. ['31I]MIBG; (b) [131I]MIBG prepared by isotopic
exchange.
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Figure 2 Tissue distribution of n.c.a. [131I]MIBG in athymic mice bearing subcutaneous SK-N-SH human neuroblastoma
xenografts in the absence (Z) and presence of various amounts of co-injected carrier MIBG (3 pg, B; 6 jg, E; 9 jug E).
Discussion
Improving the accumulation and retention of ['31I]MIBG in
neoplastic cells is one strategy for increasing the therapeutic
efficacy of this radiopharmaceutical. Since ['3'I]MIBG is
taken up in neuroblastomas and other neuroendocrine
tumours via a saturable uptake-1 mechanism (McEwan et
al., 1985; Bruchelt et al., 1995), one would expect that
tumour uptake of ["'I]MIBG could be augmented through
the use of high specific activity preparations. It has been
speculated that the pharmacokinetics of uptake and clearance
of ["'I]MIBG may be affected by the amount of carrier
MIBG which is administered (Rutgers et al., 1991; Fielding et
al., 1991) and high specific activity ['3'I]MIBG has been
advocated for therapy (McEwan et al, 1986).
Indeed, in vitro results have demonstrated the saturability ..,,,.i\xM igg
_
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of [131/1251]MIBG uptake in neuroblastoma cell lines (Bruchelt
et al., 1988; Guerreau et al., 1990; Mairs et al., 1995;
Vaidyanathan and Zalutsky, 1993; 1995). A recent report
(Mairs et al., 1995), has demonstrated that n.c.a. ['3'I]MIBG
was more effective than Ex-['31I]MIBG in the treatment of
neuroblastoma spheroids in vitro. More importantly, when
the two preparations were compared in athymic mice bearing
SK-N-BE(2C) human neuroblastoma xenografts, significantly
higher tumour uptake and tumour-to-non-target normal
tissue ratios were observed for n.c.a. [1311]MIBG.
In the current study, we have investigated the effect of
specific activity on the tissue distribution of ['31I]MIBG in
BALB/c nu/nu mice bearing SK-N-SH xenografts. We wished
to determine whether the advantage observed for n.c.a.
[13'11]MIBG localisation was related to the SK-N-BE(2C)
model or would occur in other human neuroblastoma
xenografts. The SK-N-SH xenograft was selected for
evaluation because previous in vitro studies indicated that
specific binding of the MIBG analogue meta-
[21'At]astatobenzylguanidine ([21'At]MABG) to SK-N-SH
cells was about 2-fold higher than seen in the SK-N-
BE(2C) line (Strickland et al., 1994).
The potential influence of murine strain and/or presence of
neuroblastoma xenograft on the uptake of ['31I]MIBG in
normal, innervated tissues can be appreciated by comparing
the results obtained in this study with those obtained
previously in normal animals. With n.c.a. ['31I]MIBG,
myocardial accumulation in normal BALB/c mice was about
18% ID g-1 at 4 h (Vaidyanathan and Zalutsky, 1993), a
value nearly three times that observed in BALB/c nu/lnu
animals with SK-N-SH xenografts. Decreased myocardial
and adrenal uptake of ['3'I]MIBG in tumour-bearing athymic
mice was also seen in the study reported by the Glasgow
group (Mairs et al., 1995).
In order to determine whether these differences were
related to the presence of tumour or differences in mouse
strain, an experiment was performed in which the same n.c.a.
and Ex-[13'I]MIBG preparations were administered to BALB/
c normal and athymic mice. Even in nu/nu mice without
neuroblastoma xenografts, tracer accumulation in heart and
adrenals was lower than that in normal animals. However, it
is important to note that the magnitude of the differences was
considerably less than seen in comparing normal mice with
tumour-bearing animals. As one would expect, within the
same species, carrier did reduce the myocardial uptake
considerably; however, carrier MIBG did not alter the
adrenal uptake to a significant degree.
The reduced uptake of ['31I]MIBG in the heart in tumour-
bearing mice can probably be explained by the competition of
elevated levels of endogenous catecholamines secreted by the
tumour which could block ['3'1]MIBG uptake in innervated
tissues. Several groups have observed that the presence of
neuroblastoma tumours in mice results in 3- to 10-fold higher
levels of dopamine-p-hydroxylase, the enzyme that catalyses
the conversion of dopamine to noradrenaline (Anagnoste et
al., 1972; Helson, 1975). In human phaeochromocytoma
patients, reduction in myocardial uptake of radioiodinated
MIBG has been observed, and this has been attributed to
elevated levels of catecholamines (Nakajo et al., 1983a, b).
Elevated levels of biogenic amines in the serum of tumour-
bearing mice appears to be a reasonable explanation for the
reduced heart uptake observed in these animals; however, it
does not account for the results which were obtained in
athymic mice without tumours. While it may be intriguing to
speculate that the catecholamine levels in normal and
athymic mice may be different, unfortunately, no data are
available from these animals to confirm this possibility.
The most significant observation from the current study is
that n.c.a. ['1I]MIBG uptake in SK-N-SH xenografts was not
significantly different than that seen for preparations in which
carrier MIBG was present. The fact that this occurred when
n.c.a. [13'I]MIBG was compared with both Ex-["3'I]MIBG
and n.c.a. ['3II]MIBG to which authentic MIBG carrier was
added suggests that unknown radiochemical or chemical
impurities were not a factor. Our results are contrary to those
of Mairs et al (1995) who demonstrated a significantly higher
uptake of n.c.a. ['3'I]MIBG in the SK-N-BE(2C) xenograft
model, and at least three factors could contribute to the
differences observed between the two studies.
First, the strain of mouse used by Mairs et al. (1995) was
MF1 nu/nu while our studies were performed in BALB/c nu/
nu animals. As discussed above, differences in heart and
adrenal accumulation of ['3'I]MIBG were observed between
normal and BALB/c nu/nu mice, suggesting that differences
in mouse strain may influence ['31I]MIBG tissue distribution.
One possibility is that endogenous catecholamine levels in
MFI nu/nu and BALB/c nu/nu animals may be different;
however, we are unaware of any data directly addressing this
issue.
A second difference was that our experimental protocol
involved intravenous rather than intraperitoneal administra-
tion of ['31I]MIBG. To exclude route of administration as a
factor, a paired-injection protocol was performed. Tumour
uptake of radioiodinated MIBG, as well as accumulation in
heart and adrenals, was not dependent on the route of tracer
administration.
The most important difference between the two studies is
the nature of the human neuroblastoma xenograft model.
With lower specific activity ["'lI]MIBG, similar tumour
localisation has been reported in SK-N-SH and SK-N-
BE(2C) xenografts (Gaze et al., 1994). In vitro studies have
shown that the uptake of ['31I]MIBG is saturable in both SK-
N-SH and SK-N-BE(2C) cells at a concentration of about
100 nM (Vaidyanathan and Zalutsky, 1993; Montaldo et al.,
1991). We have conducted parallel assays with both cell lines
and found similar uptake over a range of MIBG
concentrations which was saturable at 100 nM (unpublished
results). Based on these in vitro results, one would predict
that the carrier levels of MIBG used in the current study
would be sufficient to saturate uptake in SK-N-SH
xenografts.
A confounding factor which could interfere with tumour
accumulation of [13I]MIBG is the secretion of catecholamines
by the tumour. Elevated levels of endogenous catecholamines
could saturate tumour uptake and thus prevent differentia-
tion between low and high specific activity ['31I]MIBG
accumulation. In phaeochromocytoma, in vitro studies have
shown a poor correlation between MIBG uptake and cellular
catecholamine content (Jacques et al., 1987). However, unlike
phaeochromocytoma cell lines, both SK-N-SH and SK-N-
BE(2C) cells do not appear to have storage granules for
MIBG or catecholamines.
As noted above, implantation of neuroblastoma xeno-
grafts causes an increase in dopamine-fi-hydroxylase activity
in serum (Anagnoste et al., 1972; Helson et al., 1975).
However, there is little quantitative information concerning
the relative rate of catecholamine levels in different human
neuroblastoma cell lines. Tomayko et al. (1988) have
investigated catecholamine fluorescence in a number of cell
lines including SK-N-SH and SK-N-BE(2C). Interestingly,
these cell lines failed to exhibit catecholamine fluorescence in
vitro, an observation which is consistent with the binding
advantage for n.c.a. [3'I]MIBG which has been achieved in
cell culture (Vaidyanathan and Zalutsky, 1993; 1995; Mairs et
al., 1995). However, as xenografts, SK-N-BE(2C) exhibits a
low level of fluorescence while SK-N-SH tumours are
characterised by intense fluorescence. Thus, it is possible
that the higher level of catecholamines could account for the
lack of tumour uptake advantage which we observed with
n.c.a. ['31I]MIBG in SK-N-SH xenografts.
Another variable to be considered is differences in the
noradrenaline transporter (NAT), which is responsible for the
saturable, specific uptake of MIBG in neuroblastomas
(Bruchelt et al., 1995). The expression of this transporter in
neuroblastoma may be regulated by many factors which can
act differently in different cell lines. An inverse correlation
between the expression of NAT and tyrosine hydroxylase, the
key regulatory enzyme of the catecholamine synthesis, has
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been observed for SK-N-SH cells (Bruchelt et al., 1995). It
may be possible that the expression of NAT gene is
diminished for SK-N-SH cells when implanted in vivo.
Indeed, preliminary experiments using semiquantitative
reverse transcription polymerase chain reaction (Mairs et
al., 1994) indicated that receptor gene expression by SK-N-
SH, but not by SK-N-BE(2C) cells, is diminished when the
cells are grown as xenografts in MFl nu/nu mice (RT Mairs,
University of Glasgow, personal communication). If this is
true in the mouse strain we studied also, then a considerable
amount of ['31I]MIBG uptake in vivo by the uptake-I
mechanism is shut off in our model. If the majority of the
MIBG was taken up by passive diffusion, a phenomenon
favourable at higher concentrations, added carrier, as seen in
this study, could enhance the uptake.
In conclusion, our results indicate no advantage for higher
specific activity preparations of ['3'I]MIBG in the SK-N-SH
human neuroblastoma xenograft model. Further investiga-
tions are needed in other xenograft models to clarify the
factors accounting for this behaviour, particularly since the
utility of the SK-N-SH cell line as a model for neuroblastoma
has been questioned (Gaze et al., 1994). In addition, we will
soon be initiating clinical evaluation of n.c.a. ['231]MIBG in
patients with neuroendocrine tumours to determine whether
this radiopharmaceutical offers a practical advantage in
enhancing tumour localisation.
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